Daily Ards Research Analysis
Analyzed 13 papers and selected 3 impactful papers.
Summary
Analyzed 13 papers and selected 3 impactful articles.
Selected Articles
1. Systems-level insights into bronchopulmonary dysplasia from meta-analysis of genome-scale studies.
Using the MAIC algorithm to integrate genome-scale datasets across human and rodent studies, the authors identify consistent enrichment of genes involved in antigen presentation and T-cell development/activation in BPD. Limited overlap with ARDS gene sets suggests divergent mechanisms, while conserved signals (e.g., CD3E, IL1R2) highlight shared immune regulation and potential immunomodulatory targets.
Impact: This systems-level synthesis reframes BPD as a lymphoid-driven inflammatory disorder distinct from ARDS and pinpoints conserved immune regulators that can guide therapeutic development.
Clinical Implications: Findings prioritize antigen presentation and T-cell modulation pathways as targets for immunotherapies in evolving BPD, and caution against directly extrapolating ARDS mechanisms to BPD.
Key Findings
- MAIC revealed consistent enrichment of leukocyte-mediated antigen presentation and lymphocyte development/activation genes across BPD datasets.
- BPD and ARDS gene sets showed limited overlap, indicating divergent disease mechanisms with some shared immune activation pathways.
- Cross-species comparisons converged on conserved signals (e.g., CD3E, IL1R2) despite divergence in tissue remodeling signatures.
Methodological Strengths
- Systematic identification and integration of multiple genome-scale datasets using the MAIC algorithm.
- Comparative analyses across species (human and rodent) and disease contexts (BPD vs ARDS).
Limitations
- Heterogeneity in sample sources and platforms; reliance on published gene lists without uniform raw-data reanalysis.
- Lack of direct experimental validation to confirm pathway causality.
Future Directions: Prospective validation of signatures in human BPD tissues, functional perturbation of identified pathways, and early-phase trials of immunomodulatory strategies targeting antigen presentation and T-cell activation.
BACKGROUND: Despite marked improvements in survival following preterm birth, the incidence of bronchopulmonary dysplasia (BPD) remains the most prevalent complication of prematurity and carries the risk of long-term morbidity. Characterising the cellular and molecular mechanisms driving disease progression is critical for informing clinical management and improving outcomes. To this end, we conducted a meta-analysis of genome-scale studies to identify molecular pathways implicated in BPD progression in both human cohorts and animal models. METHODS: Gene lists associated with BPD in humans, and in rodent models, were extracted from systematically identified genome-scale studies. These gene lists were subsequently analysed using the meta-analysis by information content (MAIC) algorithm, which integrates multiple datasets to generate a single aggregated, ranked gene list based on the cumulative strength of evidence for each gene. Comparative analyses were then performed between the human and rodent BPD datasets, as well as between the human BPD dataset and our previously generated Acute Respiratory Distress Syndrome MAIC dataset. RESULTS: Across all analyses, a consistent enrichment of genes involved in leukocyte-mediated antigen presentation and lymphocyte development and activation was observed, suggesting a shift from acute innate immune injury toward a more sustained lymphoid-driven inflammatory process during BPD progression. Comparative analyses revealed limited overlap between BPD and ARDS gene sets, suggesting divergent disease mechanisms, while still highlighting shared immune activation pathways. Human-rodent comparisons showed divergence in tissue remodelling signatures, likely reflecting differences in sample sources, yet converged on key conserved signals such as CD3E and IL1R2, implicating common inflammatory regulatory mechanisms. CONCLUSIONS: MAIC effectively identifies conserved molecular signatures in BPD highlighting lymphoid lineage signatures that are not readily apparent in the primary data. These signatures offer insights relevant to immune-modulatory therapeutic strategies, highlighting key processes involved in antigen presentation and modulation of T-cell activation and development during the progression of Bronchopulmonary Dysplasia.
2. Epidural analgesia in labour and neonatal and childhood outcomes: national population based cohort study.
In a national cohort of 495,695 singleton labours, epidural analgesia was not associated with increased neonatal neurological morbidity or other adverse neonatal outcomes, nor with childhood cerebral palsy. Adjusted risks were close to null across subgroups including high-risk pregnancies and preterm births.
Impact: Provides robust, policy-relevant safety evidence from a large, linked administrative dataset, supporting equitable access to epidural analgesia in intrapartum care.
Clinical Implications: Clinicians can counsel patients that epidural analgesia is not associated with increased neonatal or childhood neurological harm, supporting its use without undue concern for these outcomes.
Key Findings
- No association between labour epidural and neonatal neurological morbidity (adjusted RR 0.87, 95% CI 0.68–1.12).
- No increased risk for other severe neonatal morbidity, neonatal sepsis, 5-minute Apgar <4, neonatal mortality, or childhood cerebral palsy; results consistent across subgroups.
- Epidural uptake was 23.2% among women in labour across Scotland (2007–2019).
Methodological Strengths
- Nationwide, population-based cohort with nearly half a million births and linked administrative data.
- Comprehensive outcomes with adjusted analyses and consistent subgroup findings.
Limitations
- Observational design susceptible to residual confounding and indication bias.
- Outcome ascertainment via ICD codes may introduce misclassification; limited clinical granularity.
Future Directions: Assess longer-term neurodevelopment beyond cerebral palsy, evaluate maternal outcomes and quality of analgesia, and consider quasi-experimental designs to strengthen causal inference.
OBJECTIVES: To examine whether epidural analgesia in labour is associated with neonatal neurological morbidity, other neonatal morbidity, neonatal sepsis, low Apgar score, neonatal mortality, and childhood cerebral palsy. DESIGN: National population based cohort study. SETTING: All NHS hospitals in Scotland, using Scottish NHS administrative linked data. PARTICIPANTS: 495 695 women in labour with a singleton pregnancy between 24+0 and 42+6 weeks' gestation delivering vaginally or via unplanned caesarean birth between 1 January 2007 and 31 December 2019. MAIN OUTCOME MEASURES: The primary outcome was neonatal neurological morbidity defined using ICD-10 codes as one or more of hypoxic ischaemic encephalopathy, neonatal seizures, intraventricular haemorrhage, intraventricular infarction, periventricular leukomalacia, meningitis, encephalitis, kernicterus, hypotonia, birth asphyxia, or other cerebral diagnosis occurring within 28 days of birth. Secondary outcomes were other neonatal morbidity (one or more of acidosis at birth (cord artery pH <7.10), traumatic birth injury, brachial plexus injury, necrotising enterocolitis, respiratory distress syndrome, respiratory failure, pneumothorax, hypoglycaemia, or hypothermia), neonatal sepsis, Apgar score <4 at five minutes following birth, neonatal mortality, and cerebral palsy diagnosed at any point during childhood. RESULTS: Of the 495 695 women, 114 897 (23.2%) had epidural analgesia in labour. Neonatal neurological morbidity occurred in 434 babies (0.9 per 1000 births, 95% confidence interval (CI) 0.8 to 1.0). No association was found between epidural analgesia in labour and neonatal neurological morbidity (adjusted relative risk 0.87, 95% CI 0.68 to 1.12), other severe neonatal morbidity (1.17, 0.90 to 1.51), neonatal sepsis (1.11, 0.90 to 1.37), Apgar score <4 at five minutes (0.97, 0.87 to 1.09), neonatal mortality at 28 days (0.81, 0.62 to 1.06), or cerebral palsy in childhood (0.80, 0.60 to 1.06). Findings were consistent across subgroups including women considered to have high risk pregnancies, preterm births, and across different modes of birth. CONCLUSION: Epidural analgesia during labour was not associated with clinically significant risks of harm to newborn babies or children, including risks of neonatal morbidity, death, or cerebral palsy. These findings have important policy implications, and support widening availability and equitable access to epidural analgesia as a safe component of intrapartum care.
3. Predictive Ability of Lung Ultrasound Score for Response to Surfactant Replacement Therapy in Preterm Neonates with Respiratory Distress Syndrome (PLUS-RDS Study).
In a prospective cohort of 90 preterm neonates with RDS, LUS moderately predicted response to surfactant therapy (AUC 0.721 at threshold 12) and extubation failure (AUC 0.785 at threshold 4). Findings support the use of LUS as a bedside tool to guide therapy and extubation decisions.
Impact: Offers actionable, quantitative thresholds for LUS to anticipate surfactant response and extubation outcomes, with prospective registration and standardized timing.
Clinical Implications: Incorporating LUS scoring into NICU workflows can help identify neonates likely to need surfactant retreatment and those at higher risk of extubation failure, potentially optimizing ventilation strategies.
Key Findings
- At LUS threshold 12, prediction of surfactant response yielded AUC 0.721, sensitivity 64.7%, specificity 72.9% (n=65).
- At LUS threshold 4, prediction of extubation failure yielded AUC 0.785, sensitivity 71.4%, specificity 80.0% (n=64).
- Surfactant was administered to 72.2% of enrolled neonates; 15.6% required additional doses.
Methodological Strengths
- Prospective observational design with predefined ROC analyses and registration (CTRI/2023/07/055318).
- Standardized ultrasound assessments at admission and pre-extubation.
Limitations
- Single-center study with modest sample size leading to wide confidence intervals.
- Potential operator dependence of LUS and limited external generalizability.
Future Directions: Multicenter validation, operator training standardization, and integration of LUS thresholds into decision-support algorithms for neonatal ventilation and surfactant protocols.
OBJECTIVE: To evaluate the diagnostic accuracy of lung ultrasound score (LUS) for predicting response to surfactant replacement therapy (SRT) in preterm neonates with respiratory distress syndrome (RDS). METHODS: This prospective observational study conducted between August 2023 and July 2024 enrolled consecutive neonates ≤ 34 weeks gestational age with RDS. All neonates underwent lung ultrasound following admission and prior to extubation. The LUS was compared against target condition/s (response to SRT, surfactant retreatment and extubation failure). Diagnostic accuracy measures including receiver operative characteristic (ROC) curves were estimated. RESULT: Of 126 eligible neonates, 90 neonates were enrolled. The median (q1, q3) gestational age and birth weight of the neonates were 31.2 (29.4, 32.6) weeks and 1397 (1110, 1854) g, respectively. Surfactant was administered to 65 (72.2%) neonates, and 14 (15.6%) of these required additional doses. For predicting response to surfactant therapy (n = 65, at LUS threshold 12), AUC was 0.721 (95% CI 0.572-0.870), sensitivity 64.7% (95% CI 38.3-85.8%) and specificity 72.9% (95% CI 58.1-84.7%). For predicting extubation failure (n = 64, at LUS threshold 4), AUC was 0.785 (95% CI 0.645 - 0.924), sensitivity 71.4% (95% CI 56.7 - 83.4%) and specificity 80.0% (95% CI 51.9 - 95.7%). CONCLUSION: LUS showed moderate sensitivity and specificity for predicting response to SRT and extubation failure in preterm neonates with RDS. TRIAL REGISTRY: Clinical Trial Registry-India; CTRI/2023/07/055318.